Enjoy complimentary customisation on priority with our Enterprise License!
The antidepressants drugs market share is expected to increase to USD 5.22 billion from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%.
This antidepressants drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers antidepressants drugs market segmentations by disease type (major compulsive disorder, obsessive compulsive disorder, and others) and geography (North America, Europe, Asia, and Rest of World (ROW)). The antidepressants drugs market report also offers information on several market vendors, including AbbVie Inc., Alkermes Public Ltd. Co., Bausch Health Companies Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Luye Pharma Group Ltd., MagVenture AS, Otsuka Holdings Co. Ltd., Pfizer Inc., SK Biopharmaceuticals Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. among others.
Download the Free Report Sample to Unlock the Antidepressants Drugs Market Size for the Forecast Period and Other Important Statistics
The rising prevalence of depression is notably driving the antidepressants drugs market growth, although factors such as social stigma associated with depression and lack of awareness among people may impede market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the antidepressants drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.
Key Antidepressants Drugs Market Driver
Key Antidepressants Drugs Market Trend
The development and approval of new drugs is one of the key antidepressants drugs market trends propelling the market growth. The increasing incidences of depression have led pharmaceutical vendors to develop the following new antidepressant drugs for approval:
The aforementioned instances of the development and approval of new drugs are anticipated to propel the market growth during the forecast period.
Key Antidepressants Drugs Market Challenge
The above-mentioned stigmas will reduce the adoption of new drugs and thereby will challenge the market growth during the forecast period.
This antidepressants drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.
Technavio categorizes the global antidepressants drugs market as a part of the pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the antidepressants drugs market during the forecast period.
The report analyzes the market's competitive landscape and offers information on several market vendors, including:
This statistical study of the antidepressants drugs market encompasses successful business strategies deployed by the key vendors. The antidepressants drugs market is fragmented and the vendors are deploying organic and inorganic growth strategies to compete in the market.
To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.
The antidepressants drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.
Our report provides extensive information on the value chain analysis for the antidepressants drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.
For more insights on the market share of various regions Request for a FREE sample now!
37% of the market's growth will originate from North America during the forecast period. The US and Canada are the key markets for the antidepressants drugs market in North America. Market growth in this region will be slower than the growth of the market in Europe and Asia.
Government initiatives to combat depression will facilitate the antidepressants drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.
COVID Impact and Recovery Analysis
There was a rise in the depression in the region due to the outbreak of COVID-19. Thus, the increasing cases of depression since the pandemic will lead to the approval of new antidepressant drugs in the region. Thereby, it is anticipated that the market in focus will grow positively during the forecast period.
To gain further insights on the market contribution of various segments Request for a FREE sample
The antidepressants drugs market share growth by the major compulsive disorder segment will be significant during the forecast period. Major compulsive disorder is diagnosed when an individual has a persistently low or depressed mood, anhedonia or decreased interest in pleasurable activities, and others. In 2008, major depressive disorder (MDD) has been ranked as the third cause of the burden of disease worldwide by World Health Organization (WHO), which has projected that this disease will rank first by 2030. However, FDA-approved medications for the treatment of MDD. Such an increase in major depressive disorder will drive the market growth during the forecast period.
This report provides an accurate prediction of the contribution of all the segments to the growth of the antidepressants drugs market size and actionable market insights on post COVID-19 impact on each segment.
Antidepressants Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
120 |
Base year |
2021 |
Forecast period |
2022-2026 |
Growth momentum & CAGR |
Accelerate at a CAGR of 5.44% |
Market growth 2022-2026 |
$ 5.22 billion |
Market structure |
Fragmented |
YoY growth (%) |
4.29 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 37% |
Key consumer countries |
US, Canada, Greece, China, and India |
Competitive landscape |
Leading companies, Competitive strategies, Consumer engagement scope |
Key companies profiled |
AbbVie Inc., Alkermes Public Ltd. Co., Bausch Health Companies Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., H Lundbeck AS, Johnson and Johnson, Lupin Ltd., Luye Pharma Group Ltd., MagVenture AS, Otsuka Holdings Co. Ltd., Pfizer Inc., SK Biopharmaceuticals Co. Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
We can help! Our analysts can customize this report to meet your requirements. Get in touch
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Disease Type
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.